Prof Pier Conte speaks to ecancer at ASCO 2024 about a phase III randomised trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.

He explains that patients were split 1:1 between avelumab (an immune checkpoint inhibitor) or observation.

Prof Conte reports that the primary endpoint of disease-free survival was not met but that the difference in overall survival was statistically significant in favour of avelumab.